Dividend
-
-
-
-
-
-
-
BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson’s Disease
-
-
-
-
-
-
-
BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndr
-
-
-
-
-
-
-
BioVie names Amy Chappell and Kameel Farag to board of directors
-
-
-
-
-
-
-
BioVie to Present Rationale and Design of Phase 2 SUNRISE-PD Clinical Trial at the 30th World Congress on Parkinson’s Disease and Related Disorders (IAPRD 2025)
-
-
-
-
-
-
-
BioVie Inc. Announces Closing of Registered Direct Offering
-
-
-
-
-
-
-
BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
-
-
-
-
-
-
-
BioVie Inc. (BIVI) Receives Notice of Allowance for United States Patent Application Covering Novel Liquid Formulation of Terlipressin
-
450,434 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

